Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Expands By 20.5%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 424,500 shares, a growth of 20.5% from the March 15th total of 352,300 shares. Based on an average daily trading volume, of 137,600 shares, the days-to-cover ratio is presently 3.1 days. Approximately 0.7% of the shares of the stock are sold short.

Nautilus Biotechnology Trading Up 4.8 %

NASDAQ NAUT opened at $0.76 on Monday. The business’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.80. The firm has a market capitalization of $95.62 million, a PE ratio of -1.35 and a beta of 1.39. Nautilus Biotechnology has a 12 month low of $0.66 and a 12 month high of $3.09.

Insider Activity at Nautilus Biotechnology

In other news, CEO Sujal M. Patel bought 53,300 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the transaction, the chief executive officer now owns 10,117,788 shares of the company’s stock, valued at $10,016,610.12. This trade represents a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 40.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NAUT. Barclays PLC raised its stake in Nautilus Biotechnology by 79.6% during the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock worth $303,000 after buying an additional 47,059 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Nautilus Biotechnology by 56.3% in the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares in the last quarter. Palumbo Wealth Management LLC increased its position in shares of Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after acquiring an additional 8,888 shares in the last quarter. Virtu Financial LLC bought a new stake in Nautilus Biotechnology during the 4th quarter worth approximately $28,000. Finally, JPMorgan Chase & Co. raised its position in Nautilus Biotechnology by 309.9% in the 4th quarter. JPMorgan Chase & Co. now owns 145,937 shares of the company’s stock valued at $245,000 after buying an additional 110,334 shares during the last quarter. Institutional investors own 50.71% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.